Scholarlink

Purpose <p>The present is conducted with the aim of comparing the clinical efficacy and side effects of oral versus intralesional propranolol treatment of infantile capillary hemangiomas.</p> Methods <p>Study enrolled 40 infants diagnosed with infantile capillary hemangiomas. Patients were divided into two groups:</p> <p>Group A (non-invasive group) included 20 infants who received oral propranolol hydrochloride starting with the 1&#xa0;mg/kg/day BID dose, then rose to a max of 2&#xa0;mg/kg/day BID gradually over 2&#xa0;weeks for three months.</p> <p>Group B (invasive group) included 20 infants, who received intralesional propranolol injection at a dose of 1&#xa0;mg/mL. The size of the lesion served as the factor that determined the volume of drug injection (0.2&#xa0;mL injection/cm of the diameter of the lesion), considering the use of 1&#xa0;mL for a 5-cm diameter lesion as a maximum case under complete aseptic conditions in the operating theater.</p> Results <p>At 3&#xa0;months after initiating treatment, the circumferential size of the hemangioma showed a statistically significant decrease in both groups; in group A from 3.66 ± 2.89&#xa0;cm to 1.56 ± 1.26&#xa0;cm with <i>P</i>-value &lt; 0.05 and in group B from 2.99 ± 2.73&#xa0;cm to 1.32 ± 1.18&#xa0;cm with <i>P</i>-value &lt; 0.05. There is no statistically significant comparative difference between the two groups (<i>P</i>-value = 0.538 = insignificant). Regarding the complications of oral propranolol, one patient(5%) had bradycardia, and one patient (5%) had diarrhea. In the injection group, 20 patients (100%) had local edema, and 1 patient (5%) experienced local infection.</p> Conclusions <p>Both oral non-invasive and intralesional invasive propranolol are safely and equally statistically successfully effective in the treatment of infantile hemangioma, showing reduction of the size of the hemangioma with no statistical comparative difference between both treatment techniques.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative study between oral and intralesional injection of beta-blocker in the treatment of infantile capillary hemangioma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Sahar S Sheta,
  • Kareem B. Elessawy,
  • Nadeen Eltoukhy,
  • Ayman Esmail,
  • Walaa ElNaggar

摘要

Purpose

The present is conducted with the aim of comparing the clinical efficacy and side effects of oral versus intralesional propranolol treatment of infantile capillary hemangiomas.

Methods

Study enrolled 40 infants diagnosed with infantile capillary hemangiomas. Patients were divided into two groups:

Group A (non-invasive group) included 20 infants who received oral propranolol hydrochloride starting with the 1 mg/kg/day BID dose, then rose to a max of 2 mg/kg/day BID gradually over 2 weeks for three months.

Group B (invasive group) included 20 infants, who received intralesional propranolol injection at a dose of 1 mg/mL. The size of the lesion served as the factor that determined the volume of drug injection (0.2 mL injection/cm of the diameter of the lesion), considering the use of 1 mL for a 5-cm diameter lesion as a maximum case under complete aseptic conditions in the operating theater.

Results

At 3 months after initiating treatment, the circumferential size of the hemangioma showed a statistically significant decrease in both groups; in group A from 3.66 ± 2.89 cm to 1.56 ± 1.26 cm with P-value < 0.05 and in group B from 2.99 ± 2.73 cm to 1.32 ± 1.18 cm with P-value < 0.05. There is no statistically significant comparative difference between the two groups (P-value = 0.538 = insignificant). Regarding the complications of oral propranolol, one patient(5%) had bradycardia, and one patient (5%) had diarrhea. In the injection group, 20 patients (100%) had local edema, and 1 patient (5%) experienced local infection.

Conclusions

Both oral non-invasive and intralesional invasive propranolol are safely and equally statistically successfully effective in the treatment of infantile hemangioma, showing reduction of the size of the hemangioma with no statistical comparative difference between both treatment techniques.